Skip to main content
Clinical Trials/JPRN-jRCT1051220089
JPRN-jRCT1051220089
Recruiting
N/A

A study of treatment of general malaise with human-derived mesenchymal stem cell conditioned medium

Inami Norihito0 sites20 target enrollmentSeptember 14, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Fatigue Syndrome
Sponsor
Inami Norihito
Enrollment
20
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 14, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Inami Norihito

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients who did not have a satisfactory therapeutic effect with standard treatment by a general physician
  • 2\. Patients who do not wish to be treated with the drugs used in standard treatment due to concerns about side effects, etc., and those who have been judged by the doctor that chronic pain treatment with conditioned medium is optimal.
  • Target patients who meet the following criteria.
  • 1\. 18 years old and over
  • 2\. Have normal consent ability
  • 3\. Patients who can obtain their free will consent in writing
  • 4\. Patients whose doctor have recognized the need for treatment

Exclusion Criteria

  • Patient who meet any of the following conditions are excluded
  • 1\. Have a history of or suspected of dementia
  • 2\. Users of narcotics or stimulants
  • 3\. Pregnant, breastfeeding
  • 4\. Judged unsuitable by the doctor

Outcomes

Primary Outcomes

Not specified

Similar Trials